Canada Markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
57.60-0.21 (-0.36%)
At close: 4:00PM EDT
57.74 +0.14 (+0.24%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close57.81
Open57.81
Bid57.61 x 2900
Ask57.65 x 1200
Day's Range57.44 - 58.09
52 Week Range56.66 - 69.75
Volume6,669,376
Avg. Volume9,456,564
Market Cap129.952B
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-2.76
Earnings DateNov. 03, 2021 - Nov. 08, 2021
Forward Dividend & Yield1.96 (3.20%)
Ex-Dividend DateSep. 30, 2021
1y Target Est80.24
  • Motley Fool

    2 Upcoming FDA Approval Decisions That Investors Should Really Watch

    In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.

  • GlobeNewswire

    BMY, HNST, HYZN, SAM INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: The Boston Beer Company, Inc. (SAM)Class Period: 4/22/2021 - 9/8/2021 Lead Plaintiff Motion Deadline: November 15, 2021SECURITIES FRAUD To learn more, visit https://claimsfiler.com/cases/nyse-sam/ The Honest Company, Inc. (HNST)Class Period: purchase of shares issued either in or after the May 2021 Initial Pu

  • Reuters

    Bristol Myers interested in buying Aurinia Pharma - Bloomberg News

    Aurinia's shares closed up nearly 27% on the news, giving it a market capitalization of $3.59 billion, according to Refinitiv data. The report said no final decision has been made and that Bristol Myers could opt out of a potential deal. Both Bristol Myers and Aurinia declined to comment on the matter.